에 대한 최신 뉴스 Cognex (NASDAQ:CGNX) 주식

Cognex

Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.

Cognex Corp

Goldman Sachs analyst Joe Ritchie maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Sell and lowers the price target from $39 to $35.

News

Price Target

Analyst Ratings

CGNX

Goldman Sachs Maintains Sell on Cognex, Lowers Price Target to $35

UBS analyst Damian Karas maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $58 to $56.

UBS Maintains Buy on Cognex, Lowers Price Target to $56

Baird analyst Richard Eastman maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Neutral and lowers the price target from $42 to $38.

Baird Maintains Neutral on Cognex, Lowers Price Target to $38

Truist Securities analyst Jamie Cook reiterates Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Hold and lowers the price target from $43 to $37.

Reiteration

Truist Securities Reiterates Hold on Cognex, Lowers Price Target to $37

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $45.33, a high estimate of $55.00, and a low estimate of $41.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 1.88%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739538042_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Cognex by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Piyush Avasthy</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$49.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$43.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cognex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cognex compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Cognex's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cognex's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CGNX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cognex analyst ratings.</a>
<h2>About Cognex</h2>
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
<h3>Cognex: A Financial Overview</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Cognex's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.01%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Cognex's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cognex's ROE stands out, surpassing industry averages. With an impressive ROE of 1.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.46%, the company showcases effective utilization of assets.
Debt Management: Cognex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Cognex In The Eyes Of 6 Experts

Needham analyst James Ricchiuti maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $47 to $41.

Needham Maintains Buy on Cognex, Lowers Price Target to $41

WIIM

Cognex shares are trading lower after the company reported Q4 financial results and issued Q1 revenue guidance below estimates.

Guidance

Cognex Sees Q1 Revenue $200M-$220M vs $227.2M Est.

Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. This is a 81.82 percent increase over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $229.684 million which beat the analyst consensus estimate of $220.664 million by 4.09 percent. This is a 16.79 percent increase over sales of $196.670 million the same period last year.

Earnings

Earnings Beats

Cognex Q4 2024 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $229.684M Beat $220.664M Estimate

ACRE

AEIS

AEMD

ALCO

ALKS

AMWL

ASND

ASPN

ATRC

AVXL

AYTU

BIIB

BROS

BXMT

CAMT

CHEF

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

Truist Securities analyst Jamie Cook maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Hold and raises the price target from $42 to $43.

Truist Securities Maintains Hold on Cognex, Raises Price Target to $43

Citigroup analyst Piyush Avasthy maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Neutral and lowers the price target from $44 to $42.

Citigroup Maintains Neutral on Cognex, Lowers Price Target to $42

Throughout the last three months, 5 analysts have evaluated Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cognex and provided 12-month price targets. The average target is $47.2, accompanied by a high estimate of $55.00 and a low estimate of $42.00. This current average represents a 2.68% decrease from the previous average price target of $48.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1735851621_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Cognex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$49.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cognex. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cognex compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Cognex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cognex's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CGNX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cognex analyst ratings.</a>
<h2>Get to Know Cognex Better</h2>
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
<h3>A Deep Dive into Cognex's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Cognex displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 19.01%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cognex's net margin is impressive, surpassing industry averages. With a net margin of 12.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cognex's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.93% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Cognex's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.46% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cognex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Cognex: What You Need To Know

Stephens &amp; Co. analyst Tommy Moll reiterates Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Overweight and maintains $55 price target.

Stephens & Co. Reiterates Overweight on Cognex, Maintains $55 Price Target

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Overweight rating and announces Price Target of $49.

Initiation

Cantor Fitzgerald Initiates Coverage On Cognex with Overweight Rating, Announces Price Target of $49

Truist Securities analyst Jamie Cook maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Hold and lowers the price target from $43 to $42.

Truist Securities Maintains Hold on Cognex, Lowers Price Target to $42

Highlighted on November 25, it was unveiled in an SEC filing that Sun, Director at Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: The latest Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0000851205/000177370424000011//Archives/edgar/data/851205/000177370424000011/0001773704-24-000011-index.htm">U.S. Securities and Exchange Commission</a> uncovered Sun, Director at Cognex, exercising stock options for 26,000 shares of CGNX. The total transaction was valued at $536,770.
The Tuesday morning update indicates Cognex shares down by 0.63%, currently priced at $41.27. At this value, Sun's 26,000 shares are worth $536,770.
<h3>About Cognex</h3>
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
<h3>A Deep Dive into Cognex's Financials</h3>
Revenue Growth: Over the 3 months period, Cognex showcased positive performance, achieving a revenue growth rate of 19.01% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 67.9%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Cognex's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.17.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Cognex's current Price to Earnings (P/E) ratio of 81.43 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 8.14 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 54.89, Cognex demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000851205">Check Out The Full List Of Cognex's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Witnessing An Insider Decision, Anthony Sun Exercises Options Valued At $536K At Cognex

ALGM

ANET

AVGO

AWRE

BELFB

BOXL

CLMB

CMTL

CNXN

COHR

DELL

DGII

DIOD

EVLV

EXTR

FFIV

FLEX

FORM

FRSH

IONQ

IPGP

KEYS

KODK

LASR

LITE

NOVT

NTAP

NTCT

NVEC

Next Technology Holding Inc. - Ordinary Shares

NXTT

OSIS

PLUS

PLXS

PMTS

PSTG

SANM

SCSC

SITM

TTMI

VIAV

WOLF

ZBRA

Shares of companies within the broader technology sector are trading higher in sympathy with overall market strength after Donald Trump was elected president of the United States.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58407d80aae83900016b3bd0/bryan-keane">Deutsche Bank analyst Bryan Keane</a> downgraded the rating for Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. <a href="https://www.benzinga.com/quote/MQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Jamie Cook downgraded Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. <a href="https://www.benzinga.com/quote/CGNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. <a href="https://www.benzinga.com/quote/SANA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero</a> downgraded Neumora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. <a href="https://www.benzinga.com/quote/NMRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. <a href="https://www.benzinga.com/quote/IDYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CGNX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png" alt="" class="wp-image-630098" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27.png 1272w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

IDYA

NMRA

SANA

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Truist Securities analyst Jamie Cook downgrades Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and lowers the price target from $46 to $43.

Truist Securities Downgrades Cognex to Hold, Lowers Price Target to $43

Press Releases

Cognex Launches AI-Powered Counting Tool for In-Sight SnAPP Vision Sensors

General

Vision Sensor Market Size Worth $8.33 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners

Cognex Announces Third Quarter 2024 Earnings Release and Conference Call Dates

Dividends

Cognex Declares Quarterly Cash Dividend

Cognex Reports Third Quarter 2024 Results

Cognex to Present at the Baird Global Industrial Conference

Cognex Strengthens Market Leadership in Industrial Barcode Reading with Two New AI-Powered Products

Comments

Cognex

뉴스

에 대한 최신 뉴스 Cognex (NASDAQ:CGNX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌